Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] Group 1: Market Expansion and Challenges - Chinese pharmaceutical companies are shifting their export focus from raw materials and intermediates to innovative drugs, high-end formulations, and high-performance medical devices [2] - In the first eleven months of last year, China's pharmaceutical export value reached $100.895 billion, showing steady growth, but companies face increasing risks and challenges due to rising unilateralism and protectionism [2] - The Chinese government is encouraging regions to explore building trading platforms aimed at Southeast Asia, Central Asia, and other countries to enhance international promotion and allow more nations to benefit from China's pharmaceutical industry [2] Group 2: Cross-Border Initiatives - The China-ASEAN cross-border pharmaceutical procurement platform has successfully facilitated multiple cross-border transactions, including significant orders for domestic medical devices [3] - The China-Central Asia "Central Pharmacy" initiative has attracted innovative pharmaceutical and medical device companies to showcase over 2,200 medical devices, addressing the rigid demands of Central Asian countries [3] Group 3: Pricing Mechanisms and Support - The first overseas price registration certificate for a domestic drug treating infant vascular tumors has been issued, providing a crucial basis for companies to establish reasonable pricing in international markets [4] - The National Medical Insurance Administration is developing an international pharmaceutical pricing system that allows companies to set prices based on global market conditions rather than solely on domestic insurance payment prices [5] - A new pricing mechanism for newly launched drugs will be implemented to ensure that high-investment, high-risk innovative drugs have stable prices during their initial market entry, enhancing accessibility for quality products [5]

最新数据显示，2025年，我国创新药海外授权超过150笔，总金额达到1300亿美元，2024年这一数字为500亿美元。 这是中国药械创新在国际上获得认可的一个缩影。如何让势头强劲的中国药械顺利走进全球市场？如何提高中国企业议价主动权？ "通过开展集采交易与价格平台建设，提高中国药品可及性；同时，通过健全医药价格形成机制，夯实中国药械走出去的'基本盘'。"在1月17日举办的医保 药品器械（集采）交易与价格平台支持中国药械"走出去"座谈交流活动上，国家医保局医药价格和招标采购司司长王小宁表示，中国药械"走出去"不仅是企 业的市场行为，也是一项系统工程，需要有关部门、金融机构、服务体系等同向发力。 会议现场。科技日报记者 张佳星 摄 平台铺路，"走出去"开新局 "我国药械企业出口产品已从早期的原料药、中间药、中间体，转向创新药、高端制剂、高性能医疗器械等领域。"工业和信息化部消费品工业司二级巡视员 邓小丁表示，越来越多企业开展国际多中心临床试验、申请欧美认证、在海外设立研发中心与生产基地、积极融入全球创新链与市场网络。 去年前11个月，我国医药出口额1008.95亿美元，规模稳步提升，但企业走出去仍面临诸多风险挑战 ...

中新社北京1月17日电 (记者 李纯)"在全球化发展的赛道上，跨国平台可以起到帮助医药企业挺直腰 杆、擦亮招牌、架桥铺路的作用。"中国国家医疗保障局医药价格和招标采购司司长王小宁如是形容搭 建平台对助力中国药械"走出去"的重要性。 中国药登负责人李克斌介绍说，截至1月16日，中国药登已有60家申请注册企业，登记药品22个，涵盖 中成药、化药、生物制药等类型。中国药登还将搭建国际互认机制，增强全球公信力，提高药械准入手 续的办理效率。 不只是中国药登，当前，中国已建成中国—东盟区域医药交易(集采)平台、中国(新疆)—中亚"中心药 房"等多个药械(集采)交易与价格平台，助力中国质优价宜的药品、医疗器械进入国际市场。 其中，2025年1月9日，中国—东盟区域医药交易(集采)平台启动仪式在广西举行。广西医保局副局长赖 永东表示，如今，该平台建设运行已取得初步成效，药械交易金额突破1000万元(人民币)，药品涉及多 家医药企业的多项产品，覆盖东南亚多国。 此外，中国还有多个药械(集采)交易与价格平台正处于建设阶段。据天津医保局二级巡视员吴刚介绍， 中国国际医疗设备与器械交易(集采)平台预计将于今年2月上旬正式揭牌上线。 ...